VR Logo

Unrated

ITI Pharma and Healthcare Fund - Direct Plan download report


Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
ITI Pharma and Healthcare Fund Direct-G -14.43 0.78 0.53 -0.77 -8.24 -14.43 -- -- -- -- --
S&P BSE Healthcare TRI -16.82 0.62 0.34 -2.06 -10.68 -16.82 -- -- -- -- --
Equity: Sectoral-Pharma -14.86 0.72 0.55 -1.28 -9.18 -14.86 -- -- -- -- --
Rank within category 4 5 5 3 3 4 -- -- -- -- --
Number of funds in category 11 11 11 11 11 11 10 8 4 3 0

As on 01-Jul-2022

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
ITI Pharma and Healthcare Fund - Direct Plan
Unrated
Nov-21 -- -- -- 0.32% 159
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 -13.45 23.60 16.40 1.04% 4,516
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 -11.23 24.31 -- 1.23% 2,316
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 -9.01 28.10 -- 0.64% 1,692
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 -12.50 23.40 11.02 1.07% 1,638

Best & Worst Performance

Best Performance Worst Performance
Return (%) Period Return (%) Period
Week 4.87 24-Dec-2021 - 31-Dec-2021 -6.42 02-May-2022 - 10-May-2022
Month 8.21 07-Mar-2022 - 06-Apr-2022 -10.34 12-Apr-2022 - 12-May-2022
Quarter 0.27 24-Feb-2022 - 26-May-2022 -10.98 25-Nov-2021 - 24-Feb-2022
Year -- - -- -

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
ITI Pharma and Healthcare Fund Direct-G -- -- -- -- -- --
S&P BSE Healthcare TRI* 20.37 22.36 0.75 1.50 -- --
Equity: Sectoral-Pharma* 23.61 20.44 0.99 2.00 0.89 5.06
Rank within category -- -- -- -- -- --
Number of funds in category -- -- -- -- -- --

The Risk Measures have been calculated using calendar month returns for the last three years.

As on

* As on 30-Jun-2022

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 31
Top 10 Stocks (%) 70.37
Top 5 Stocks (%) 47.88
Top 3 Sectors (%) 99.30
Portfolio P/B Ratio 4.15
Portfolio P/E Ratio 32.83

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 36,567 55,629
Giant (%) 20.24 19.21
Large (%) 28.17 38.04
Mid (%) 39.15 35.58
Small (%) 12.44 7.07
Tiny (%) -- 0.73

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
down Sun Pharmaceutical Industries Healthcare 60.92 20.57 16.85 20.10
down Torrent Pharmaceuticals Healthcare 63.16 8.15 4.90 7.96
down Lupin Healthcare -- 9.74 0.00 7.76
down Dr. Reddy's Lab Healthcare 33.06 9.91 0.00 6.12
down Divi's Laboratories Healthcare 32.63 6.94 0.00 5.94
up Cipla Healthcare 29.83 5.77 0.00 5.77
down Glaxosmithkline Pharma Healthcare 15.31 6.02 2.89 5.05
down Natco Pharma Healthcare 69.26 5.31 4.48 4.48
down Alkem Laboratories Healthcare 22.10 3.93 0.00 3.61
down Astec Lifesciences Chemicals 41.56 3.58 0.00 3.58
down Narayana Hrudayalaya Healthcare 38.20 2.73 0.00 2.58
down Ajanta Pharma Healthcare 22.29 3.02 2.00 2.50
down Suven Pharmaceuticals Healthcare 25.64 3.17 2.36 2.36
down Healthcare Global Enterprises Healthcare 69.86 2.13 0.00 2.02
down FDC Healthcare 18.96 1.92 0.94 1.88
down Fortis Healthcare Healthcare 32.84 2.05 0.00 1.81
down Kovai Medical Center Healthcare 15.65 1.90 0.00 1.73
down Aster DM Healthcare Healthcare 16.87 1.61 0.93 1.61
down JB Chemicals & Pharma Healthcare 31.73 1.61 0.00 1.60
down Max Healthcare Institute Healthcare 58.65 1.54 0.69 1.52
down Gujarat Fluorochemicals Chemicals 38.17 1.14 0.00 1.14
down SBI Life Insurance Company Insurance 59.06 4.92 0.97 1.10
down ICICI Lombard General Insurance Company Insurance 44.90 1.34 0.94 1.08
new Zydus Lifesciences Healthcare 8.21 1.05 0.00 1.05
down Syngene International Healthcare 56.32 1.45 0.00 0.98

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 31-May-2022

Fund Manager

— Hetal Gada since 29-Apr-2022

Education: Ms. Gada has done MBA (Finance)

Experience: Prior to joining ITI AMC, she worked with Centrum where she handled research in auto and consumer sector. Prior to that, she worked with Elara Securities for 2 years and CRISIL for more than 3 years, both where she handled research on various sectors including metals.

Funds Managed:

— Pratibh Agarwal since 29-Apr-2022

Education: Mr. Agarwal is a Masters of Technology (IIT Kanpur)

Experience: Prior to joining ITI Asset Management, he has worked with Nippon India Asset Management as Research Associate, Yoctel Solutions Ltd. as Senior Consultant, Alcatel Lucent Ltd as Engineer.

Funds Managed:

— Rohan Korde since 18-Oct-2021

Education: Mr. Korde is a Masters in Management Studies (Finance), Bachelor of Commerce

Experience: Prior to joining Asset Management Limited, he has worked with BOB Capital Markets as Vice President Research, Prabhudas Lilladher as Vice President Research and Anand Rathi Share & Stock Brokers as Vice President Research.

Funds Managed:


0.78%

Change from previous, NAV as on 01-Jul-2022

Growth: ₹ 8.8148

IDCW: ₹ 8.8148


Investment Strategy

The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.

Investment Details

Min. Investment (₹) 5,000
Min. Addl Investment (₹) 1,000
Min. SIP Investment (₹) 500
Min. No of Cheques 12
Min. Withdrawal (₹) 1,000
Min. Balance (₹) --
Lock-in Period Not Applicable
Exit Load 1% for redemption within 365 days

Basic Details

Fund House: ITI Mutual Fund
Launch Date: 08-Nov-2021
Return Since Launch: -11.85%
Benchmark: NIFTY Healthcare TRI.
Riskometer: Very High
Type: Open-ended
Assets: ₹ 159 Cr (As on 31-May-2022)
Expense: 0.32% (As on 31-May-2022)
Risk Grade: --
Return Grade: --
Turnover: --

Contact Information

AMC: ITI Asset Management Ltd.

Address: ITI Asset Mangement Limited, ITI House, Building no. 36, Dr. R. K. Shirodkar Marg, Parel, Mumbai - 400012

Phone: 022-66214999

Email: [email protected]

Website: http://www.itiamc.com

Registrar & Transfer Agent: KFin Technologies Ltd.

Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016

Phone: 040-44857874

Email: [email protected]

Website: www.karvymfs.com

Upcoming Video

Investors' Hangout

All about nominations in mutual funds

DateFri, 08-Jul-2022
Time12:30 PM - 12:40 PM

attending You have reserved a spot